Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2020

View Archived Issues

Enrollment ongoing in phase I/II study of oral BDTX-189 in advanced solid tumors

Sanofi initiates phase III study of SAR-408701 in CEACAM5-positive metastatic nonsquamous NSCLC

Novel muraminomicin derivatives with potent activity in MRSA infection models

OXi-4503 in combination with ARA-C shows safety and early clinical efficacy in AML

ASIT Biotech publishes phase III data for gp-ASIT+ grass allergen peptide immunotherapy

Suzhou Mednes Pharma Tech patents hedgehog signaling inhibitors

Roche discloses new EGFR mutant inhibitors

B cells help T cells succeed during checkpoint blockade

Single transcription factor enables chronic toxoplasma infection

AlzeCure Pharma presents Trk-A and/or Trk-B and/or Trk-C modulators

Meiji Seika Pharma describes new PDE4 inhibitors

New compounds for Huntington's disease presented by PTC Therapeutics

Pfizer begins phase III study of PF-06801591 in high-risk nonmuscle invasive bladder cancer

Xalud starts phase II study of XT-150 for pain due to knee osteoarthritis

SUMOylation inhibition enhances targeting of farnesoid X receptor for liver fibrosis

Kadmon discloses new SLC2A3 inhibitors

Oncogene Ras affects memory consolidation

Phase III study of surufatinib in pancreatic neuroendocrine tumors stopped early for efficacy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...